On April 11, 2017, the CDCN
 announced a collaboration with Janssen Research & Development, LLC, to conduct a proteomics study of idiopathic multicentric Castleman disease (iMCD). The Press Release in BusinessWire stated "the collaboration combines CDCN’s strong expertise in iMCD research and its world-wide network of physician researchers with Janssen’s industry leading iMCD research resources". During this study, collaborators will measure the "level of approximately 1,300 analytes in more than 260 serum samples collected from approximately 100 iMCD patients at various time points during active disease". Read the full press release here: http://www.businesswire.com/news/home/20170411006057/en

To contribute samples to research, please visit: cdcn.org/samples
To learn about ongoing research studies, please visit: http://www.cdcn.org/research-pipeline

Comments

There are no comments yet.

Leave a Comment